Tharun is a Chartered Financial Analyst from the CFA Institute, U.S. A graduate from Loyola College, Chennai, he started his career in Goldman Sachs at their Bangalore office. Prior to his current role at Proactive Investors, he worked as an equity analyst at a global research and analytics company in Mumbai, assisting institutional clients across Asia.
Patients can access the company's drug through the TGA special access scheme.
Discovered a compound that is a potent inhibitor of IRAK4 protein which causes chronic inflammation including autoimmune diseases.
CannPal plans to take the results from its recently commenced phase 1A and B studies to file an Investigational New Animal Drug application with the FDA.
KEY-Vaxx has shown potential in preclinical studies, outperforming an industry-standard antibody.
The latest investment takes Star Bright’s total interest in the company to 19.99% of issued shares.
Non-executive director Dennis Eck purchased $1 million worth of stock for 38 cents.
The offer was at the same price as the recent share placement to sophisticated and institutional investors for $9 million.
Arix led a $24 million share placement and will invest $14.2 million in two tranches.